Kiniksa Pharmaceuticals, Ltd.

Historical 13F Holders

Symbol
KNSA
CUSIP
G52694109
All holders as of
Q2 2026
Type
Equity
Class
ORD SHS CL A
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for G52694109 since 12/18/2024, newest first.

Filer % of Class Filed
BlackRock, Inc. 13G 5.5% 7/29/2026
Event 6/30/2026
Baker Bros. Advisors LP 13D/A Amendment 6
7.0% 5/26/2026
Event 5/21/2026
FMR LLC 13G/A Amendment 1
14.8% 5/6/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 7 0% 3/27/2026
Event 3/13/2026
FMR LLC 13G
10.6% 3/6/2026
Event 2/27/2026
Rubric Capital Management LP 13G/A Amendment 4
7.4% 2/13/2026
Event 12/31/2025
Vanguard Group Inc 13G/A Amendment 6 7.0% 10/31/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 4 1.0% 7/17/2025
Event 6/30/2025
Rubric Capital Management LP 13G/A Amendment 3
9.2% 7/9/2025
Event 6/30/2025
Rubric Capital Management LP 13G/A Amendment 2
8.1% 5/14/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 3 5.4% 4/23/2025
Event 3/31/2025
Tang Capital Management LLC 13G
5.2% 4/4/2025
Event 3/28/2025
Fairmount Funds Management LLC 13G/A Amendment 3
0% 2/14/2025
Event 12/31/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 51.2 k $3.82 M
2026 Q2 279 49.7 M $3.04 B
2026 Q1 235 45.4 M $2.18 B
2025 Q4 232 43.0 M $1.77 B
2025 Q3 212 41.0 M $1.59 B
2025 Q2 197 40.8 M $1.13 B
2025 Q1 184 40.0 M $888 M
2024 Q4 166 39.0 M $771 M
2024 Q3 185 39.7 M $993 M
2024 Q2 135 37.2 M $695 M